WDR86-AS1: A Potential Drug Target and Biomarker (G100131176)

Target Name: WDR86-AS1

NCBI ID: G100131176

WDR86-AS1

Other Name(s): WDR86 antisense RNA 1 | WDR86 antisense RNA 1, transcript variant 1

WDR86-AS1: A Potential Drug Target and Biomarker

WDR86-AS1, also known as WDR86-AS1 gene, is a non-coding RNA molecule that has been identified as a potential drug target and biomarker. The molecule is located on chromosome 8q22 and has been shown to play a role in various cellular processes, including cell adhesion, migration, and survival.

WDR86-AS1 functions as a negative regulator of the TGF-β pathway, which is a well-known regulator of cell growth and differentiation. The TGF-β pathway is involved in the development, maintenance, and regression of tissues and organs, and is a key target for many diseases, including cancer.

Several studies have suggested that WDR86-AS1 may be a promising drug target due to its unique structure and its involvement in the TGF-β pathway. The molecule has been shown to interact with several TGF-β ligands, including SMAD4 and ALK3. This suggests that WDR86-AS1 may be a negative regulator of TGF-β signaling that can be targeted with drugs that can inhibit its activity.

In addition to its potential as a drug target, WDR86-AS1 has also been identified as a potential biomarker for several diseases, including cancer. The molecule has been shown to be expressed in a variety of tissues and organs, including lung, breast, and ovarian cancer. Additionally, studies have shown that high levels of WDR86-AS1 expression are associated with poor prognosis in cancer patients.

The identification of WDR86-AS1 as a potential drug target and biomarker has implications for the development of new treatments for a variety of diseases. By targeting WDR86-AS1 with drugs that can inhibit its activity, researchers may be able to develop new treatments for diseases that are currently untreatable or have limited treatment options. Additionally, the molecule's potential as a biomarker for cancer has significant implications for the early detection and treatment of this disease.

In conclusion, WDR86-AS1 is a non-coding RNA molecule that has been identified as a potential drug target and biomarker. Its unique structure and involvement in the TGF-β pathway make it an attractive target for drug development, and its potential as a biomarker for cancer has significant implications for the early detection and treatment of this disease. Further research is needed to fully understand the role of WDR86-AS1 in cellular processes and its potential as a drug and biomarker.

Protein Name: WDR86 Antisense RNA 1

The "WDR86-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about WDR86-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets